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Racial and ethnic disparities in lung cancer incidence remain a significant health concern.1,2 
In the United States, when compared with non-Hispanic white (NHW) individuals, non-
Hispanic black (NHB) individuals experience higher incidence rates of lung cancer, whereas 
Hispanic individuals experience lower incidence rates of the disease.3,4 Contemporary 
examination of lung cancer incidence trends, specifically by histology, can inform the extent 
to which progress in national declines in incidence is observed across all segments of the 
population. The article by Lewis et al,5 which presented 33 years of data from the National 
Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program, described 
the incidence trends of lung cancer histologies by sex and race/ethnicity. The authors 
reported a steady decline in the rates of squamous cell, small cell, and adenocarcinoma 
subtypes until 2005. After 2005, rates of adenocarcinoma for males increased. This 
interesting finding most likely reflects temporal changes in more accurate specification of 
lung cancer histologic subtypes.6,7 Although Lewis et al5 reported variation in trends by 
histology, sex, and race/ethnicity, we believe that the dramatically differing trends by race/
ethnicity warrant further highlight and discussion.
In our own analysis of SEER data, which included the period 1992 through 2011, we 
similarly found that incidence declines were most pronounced for small cell in comparison 
with non-small cell subtypes for NHW and NHB males, reflecting progress in tobacco 
control in these populations. However, the differences across racial/ethnic groups in the 
incidence trends of non-small cell lung cancer, specifically adenocarcinoma and squamous 
cell carcinoma, is worth highlighting. Similar to the findings reported by Lewis et al,5 in our 
analysis, NHW males experienced an increased incidence from 2005 through 2011 of the 
squamous cell subtype (annual percent change [APC], 1.9; 95% confidence interval [95% 
CI], 1.0–2.7), whereas there was a steady decline in this subtype across all years of the study 
for NHB and Hispanic males. The incidence for adenocarcinoma increased among NHW 
and NHB males from 2005 through 2011. However, Hispanics males experienced a 
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significant decline in all lung cancer histologic subtypes including adenocarcinoma. Among 
females, we concur that lung cancer incidence rates have been relatively stable, with 
evidence of more recent declines since 2005 noted among NHB and NHW females. As with 
males, the incidence in small cell lung cancer declines was largest for NHB females (1992–
2011: APC, −1.3; 95% CI, −2 to −0.5) and NHW females (1992–2004: APC, −5; 95% CI, 
−6 to −3.8; and 1996–1999: APC, −1.7; 95% CI, −2.3 to 1.1). In our join-point analysis, 
Hispanic females experienced a brief increase of 7.9% per year in the incidence rate of the 
small cell subtype from 2004 through 2009, which then declined by 17.4% per year (95% 
CI, −30 to −2.6) until 2011. Among females, the differences in trends by race/ethnicity were 
most pronounced for adenocarcinoma, with a steady and highest rate of increase noted 
among Hispanic (APC, 5.8; 95% CI, 1.9–9.9) and NHB (APC, 3.2; 95% CI, 2.3–4.1) 
females from 2006 through 2011, whereas rates among NHW females remained stable or 
increased (1992–2005: APC, 0.3; 95% CI, −0.2 to −0.7; and 2005–2011: APC, 2.4; 95% CI, 
1.1–3.7).
The challenge remains to understand how much of these variations in incidence trends are 
simply due to improvements in coding from “not otherwise specified” to specific histologies 
and how much reflects actual disparities that may be mediated by other factors such as 
socioeconomic status or access to high-quality cancer care pathologists. Given the larger 
trend differences in adenocarcinoma compared with the category of “not otherwise 
specified” in recent years among all ethnicities (2005–2011: APC range, −10 to −24.7), it is 
reasonable to surmise that these trends indeed reflect meaningful racial/ethnic differences. 
However, it is also worth considering whether the differences in incidence trends of 
adenocarcinoma noted among Hispanic females versus Hispanic males reflect differences in 
smoking patterns as suggested by Lewis et al5 or other social determinants of health such as 
access to quality pathology review. Regardless, the racial/ethnic differences in histologic-
specific incidence rates of lung cancer noted among males and females warrant further 
investigation.
We are encouraged to observe the overall decline in histologic-specific incidence rates of 
lung cancer. However, when examined through a lens of racial/ethnic disparities, these 
findings reveal the need for a broader discussion of the underlying factors that may be 
driving the unequal burden of lung cancer across populations. As suggested by Lewis et al,5 
smoking trends and cessation rates may be possible explanations for these variations in 
incidence trends by histology and race/ethnicity.5,8 However, genetic, environmental, and 
socioeconomic factors may also play an important role in these changing trends. Further 
studies should investigate how these factors may influence the trends reported by Lewis et 
al.5
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